Firm
Publication of the UPC’s annual report and adoption of the procedural rules of the Patent Mediation and Arbitration Centre were also among major developments
Tarun Khurana, founding partner of Khurana & Khurana, discusses juggling tasks, why every hour has a value, and the importance of ‘trusting the process’
The variety of winners demonstrates that the UPC is now a core benchmark rather than an experimental consideration, while junior lawyers are becoming more deeply involved in key work
Sheppard, which has hired 14 IP partners in the last 12 months, has cited client demand for expert counsel in SEP, ITC, and district court disputes
Sponsored
Sponsored
-
Sponsored by InventaInês Monteiro Alves of Inventa analyses the trademark implications resulting from the acquisition of the fact-checking TV programme from the broadcaster SIC -
Sponsored by United Trademark & Patent ServicesM Talal Farrukh Irfan Khan of United Trademark & Patent Services explores the UAE’s evolving approach to AI regulation, combining federal and sector-specific legislation, free zone frameworks, and national policy initiatives
-
Sponsored by Hanol IP & LawA landmark case involving the remodelling of luxury brand bags at the owner’s request has established legal principles on the trademark implications of such services, explains Min Son of Hanol IP & Law
-
Sponsored by Patrinos & KilimirisMaria Kilimiris of Patrinos & Kilimiris explains a recent decision regarding how genuine use is assessed for trademarks registered across broad categories of goods and their subcategories
-
Sponsored by Berken IPMaría Aurora García of Berken IP examines how Argentine courts are using dynamic injunctions to tackle illegal sports streaming, particularly in the context of major events such as the football World Cup
-
Sponsored by Bird & BirdAnnika Lückemann and Jan van Dieck of Bird & Bird analyse the Unified Patent Court’s opening ruling concerning a supplementary protection certificate, highlighting procedural peculiarities, urgency considerations, and possible implications for pharmaceutical originator-generic disputes
